Literature DB >> 15167910

Platelet function and its clinical significance in the myelodysplastic syndromes.

Aliza Zeidman1, Nir Sokolover, Zinaida Fradin, Amos Cohen, Ophra Redlich, Moshe Mittelman.   

Abstract

The current study was aimed at investigating platelet function in MDS and its clinical significance. There were 23 patients with untreated MDS at presentation, including refractory anemia (RA), RA with ringed sideroblasts, RA and excess blasts and chronic myelomonocytic leukemia RAEBt. The mean platelet count was 167.9 x 109/L. Patients with a platelet count less than 70 x 109/l were excluded. The mean bleeding time (BT) was 2.7 min. Only four MDS patients had BT longer than the normal 1-4 min range. Platelet aggregation (PA) was studied with epinephrine (Epi), ADP, arachidonic acid (AA), ristocetin and collagen. Overall, 16 (70%) patients had PA abnormality, 65% had impaired Epi-induced PA, 57% demonstrated reduced ADP-induced PA. AA, ristocetin and collagen was decreased PA in 48, 22 and 17%, respectively. Five patients (22%) demonstrated spontaneous PA. Only seven patients (30%) were found to have normal PA with all five inducers. Six (26%) patients had spontaneous mild bleeding and all six bleeding MDS patients demonstrated at least one abnormal platelet function. The only bleeding patient with all five PA tests normal demonstrated prolonged BT. In the present study of 23 newly diagnosed MDS patients, PA abnormalities were relatively common, the BTs were usually normal, and bleedings were relatively uncommon and mild at platelet count between 70 and 397 x 109/l.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167910     DOI: 10.1038/sj.thj.6200364

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  7 in total

1.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

2.  Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.

Authors:  Julia Fröbel; Ron-Patrick Cadeddu; Sonja Hartwig; Ingmar Bruns; Christian M Wilk; Andrea Kündgen; Johannes C Fischer; Thomas Schroeder; Ulrich G Steidl; Ulrich Germing; Stefan Lehr; Rainer Haas; Akos Czibere
Journal:  Mol Cell Proteomics       Date:  2013-02-04       Impact factor: 5.911

Review 3.  Management of myelodysplastic syndromes: 2008 update.

Authors:  Bart L Scott; Eli Estey
Journal:  Oncology (Williston Park)       Date:  2008-11-15       Impact factor: 2.990

Review 4.  Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

Authors:  Maria Sanz-De Pedro; Wei Wang; Rashmi Kanagal-Shamanna; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

5.  Acute adrenal insufficiency as a first presentation of myelodysplastic syndrome and sigmoid colon adenocarcinoma: a case report.

Authors:  Angeliki Kleanthous; Elena Koushiappi; Yiolanda Herodotou; Elena Xenofontos; Emmelia Vounou
Journal:  Oxf Med Case Reports       Date:  2014-08-07

6.  Lobectomy for lung cancer in a myelodysplastic syndrome patient with decreasing platelet aggregation: report of a case.

Authors:  Satoshi Koezuka; Yoshinobu Hata; Hajime Otsuka; Takashi Makino; Yoko Azuma; Takashi Azumi; Yoichi Anami; Kazuhiko Natori; Akira Iyoda
Journal:  J Cardiothorac Surg       Date:  2018-07-24       Impact factor: 1.637

Review 7.  Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem.

Authors:  May Basood; Howard S Oster; Moshe Mittelman
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.